More Innovative Hypertension Treatments On The Horizon As Patents Expire In Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - A Daiichi Sankyo announcement that its hypertension treatment, olmesartan (Benicar in the United States), has demonstrated effectiveness for preventing or reversing the narrowing of arteries in high blood-pressure patients may be a precursor to a rash of Japanese drug makers' similar findings in the coming months as the patents of many of their globally-distributed products expire around 2010, a securities company strategist said June 20
You may also be interested in...
Astellas Expansion Of Domestic Sales Impressive Despite NHI Pricing; Launches Mycamine in U.K.
TOKYO - Astellas' Japanese domestic sales expanded 4.5 percent compared to last year, which analysts said were impressive because of the lowering of the National Health Insurance pricing across the board in April. The company attributed the increase to sales of long-acting angiotensin-II receptor antagonist Micardis (telmisartan), the hypnotic Myslee, and a few other products
Astellas Expansion Of Domestic Sales Impressive Despite NHI Pricing; Launches Mycamine in U.K.
TOKYO - Astellas' Japanese domestic sales expanded 4.5 percent compared to last year, which analysts said were impressive because of the lowering of the National Health Insurance pricing across the board in April. The company attributed the increase to sales of long-acting angiotensin-II receptor antagonist Micardis (telmisartan), the hypnotic Myslee, and a few other products